NCT04562922View on ClinicalTrials.gov

LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 11, 2013

Primary Completion Date

May 26, 2014

Study Completion Date

April 4, 2016

Conditions
NeutropeniaAdverse Event
Interventions
DIETARY_SUPPLEMENT

Lifemel

All Listed Sponsors
lead

VitalMel

INDUSTRY

NCT04562922 - LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy | Biotech Hunter | Biotech Hunter